The path to personalized medicine in asthma

References

• [cited 2016 Mar 2]. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf
   Google Scholar
• Baroffio M, Barisione G, Crimi E, et al. Noninflammatory mechanisms of airway hyper-responsiveness in bronchial asthma: an overview. Ther Adv Respir Dis. 2009 Aug;3(4):163–174.
   PubMedGoogle Scholar
• Vianello A, Caminati M, Crivellaro M, et al. Fatal asthma. Still an epidemics? World Allergy Organ J. Forthcoming 2016.
   Google Scholar
• De Ferrari L, Chiappori A, Bagnasco D, et al. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med. 2016 Jan;10(1):29–38.
   PubMed Web of Science ®Google Scholar
• DeKruyff RH, Yu S, Kim HY, et al. Innate immunity in the lung regulates the development of asthma. Immunol Rev. 2014;260:235–248.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016 Apr;16(2):186–200.
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016 Jan;7(1):34–51.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-il-13 and il-4 strategy in severe asthma. Int Arch Allergy Immunol. Forthcoming 2016.
   Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127:382–389.
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113:101–108.
   PubMed Web of Science ®Google Scholar
• Kim JY, Sohn JH, Lee JH, et al. Obesity increases airway hyperresponsiveness via the TNF-α pathway and treating obesity induces recovery. PLoS One. 2015 Feb 6;10(2):e0116540.
   PubMed Web of Science ®Google Scholar
• Hilda Segura N, Hernández L, Velázquez C, et al. Asthma and obesity: related inflammatory diseases. Rev Alerg Mex. 2007 Jan–Feb;54(1):24–28.
   PubMedGoogle Scholar
• Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011;127(1486–93):e2.
   PubMed Web of Science ®Google Scholar
• Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011;128:508–515. e2.
   PubMed Web of Science ®Google Scholar
• Lombardi C, Gargioni S, Gardinazzi A, et al. Impact of bariatric surgery on pulmonary function and nitric oxide in asthmatic and non-asthmatic obese patients. J Asthma. 2011;48:553–557.
   PubMed Web of Science ®Google Scholar
• Baines KJ, Simpson JL, Wood LG, et al. Transcriptional phenotypes of asthma defined by gene expression profiling in induced sputum sample. J Allergy Clin Immunol. 2011;127:153–160.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549–558.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42:1097–1103.
   PubMed Web of Science ®Google Scholar
• Brusselle GG. Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases? Thorax. 2015 May;70(5):401–403.
   PubMed Web of Science ®Google Scholar
• Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87:1541–1546.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the “precision medicine”. Clin Mol Allergy. 2015 Oct 8;13:24.
   PubMedGoogle Scholar
• Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol. 2007 Dec;120(6):1269–1275.
   PubMed Web of Science ®Google Scholar
• Ferrando M, Bagnasco D, Braido F, et al. Biosimilars in allergic diseases. Curr Opin Allergy Clin Immunol. 2016 Feb;16(1):68–73.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014 Nov;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014 Jul 2;6(243):243ra85.
   PubMed Web of Science ®Google Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015 Feb;135(2):299–310.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858–15863.
   PubMed Web of Science ®Google Scholar
• Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211–1221.
   PubMed Web of Science ®Google Scholar
• Tambor V, Fucíková A, Lenco J, et al. Application of proteomics in biomarker discovery: a primer for the clinician. Physiol Res. 2010;59:471−497.
   PubMed Web of Science ®Google Scholar
• Mikami T, Aoki M, Kimura T. The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development. Mol Pharmacol. 2012;5:301−316.
   Google Scholar
• Teran ML, Montes-Vizuet R, Li X, et al. Respiratory proteomics: from descriptive studies to personalized medicine. J Proteome Res. 2015;14:38−50.
   PubMed Web of Science ®Google Scholar
• Lindskog C, Fagerberg L, Hallström B, et al. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. Faseb J. 2014 Dec;28(12):5184–5196.
   PubMed Web of Science ®Google Scholar
• Priyadharshini VS, Teran LM. Personalized medicine in respiratory disease: role of proteomics. Adv Protein Chem Struct Biol. 2016;102:115–146.
   PubMedGoogle Scholar
• Wu J, Kobayashi M, Sousa EA, et al. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol Cell Proteomics. 2005;4:1251−1264.
   PubMed Web of Science ®Google Scholar
• Cederfur C, Malmström J, Nihlberg K, et al. Glycoproteomic identification of galectin-3 and −8 ligands in bronchoalveolar lavage of mild asthmatics and healthy subjects. Biochim Biophys Acta. 2012;1820:1429−1436.
   PubMed Web of Science ®Google Scholar
• O’Neil SE, Sitkauskiene B, Babusyte A, et al. Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. Respir Res. 2011;12:124.
   PubMed Web of Science ®Google Scholar
• Singh A, Cohen Freue GV, Oosthuizen JL, et al. Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge. Proteomics Clin Appl. 2012;6:476−485.
   PubMed Web of Science ®Google Scholar
• Gharib SA, Nguyen EV, Lai Y, et al. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol. 2011;128:1176−1184.
   PubMed Web of Science ®Google Scholar
• Lee TH, Jang AS, Park JS, et al. Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann Allergy Asthma Immunol. 2013;111:268−275.
   PubMed Web of Science ®Google Scholar
• Ko YC, Hsu WH, Chung JG, et al. Proteomic analysis of CD4+ T-lymphocytes in patients with asthma between typical therapy (controlled) and no typical therapy (uncontrolled) level. Hum Exp Toxicol. 2011;30:541−549.
   PubMed Web of Science ®Google Scholar
• Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014;162(1Pt A):2–10.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL, Hankin R, et al. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax. 2003;58:116–121.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001–1008.
   PubMed Web of Science ®Google Scholar
• Rossi R, De Palma A, Benazzi L, et al. Biomarker discovery in asthma and COPD by proteomic approaches. Proteomics Clin Appl. 2014;8:901–915.
   PubMed Web of Science ®Google Scholar
• Wagener AH, De Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120.
   PubMed Web of Science ®Google Scholar
• Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133:388–394.
   PubMed Web of Science ®Google Scholar
• Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax. 2012;67:1061–1066.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.
   PubMed Web of Science ®Google Scholar
• Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25:475–484.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of Omalizumab in allergic asthma. an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811.
   PubMed Web of Science ®Google Scholar
• Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014;49:624–631.
   PubMed Web of Science ®Google Scholar
• Carraro S, Giordano G, Reniero F, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy. 2013;68:110–117.
   PubMed Web of Science ®Google Scholar
• Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung. 2007;185:105–112.
   PubMed Web of Science ®Google Scholar
• Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974–82.e13.
   PubMed Web of Science ®Google Scholar
• Peck R, Smith P. Beyond genetics – stratified and personalised medicines using multiple parameters. Pharmaceuticals. 2010;3(5):1637–1651.
   Google Scholar
• Sippel JM, Holden WE, Tilles SA, et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol. 2000 Oct;106(4):645–650.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170–14175.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF Jr, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098.
   PubMed Web of Science ®Google Scholar
• Horváth I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. ATS/ERS Task Force on Exhaled Breath Condensate. Eur Respir J. 2005 Sep;26(3):523–548.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhou J, Bi H, et al. CCL-11 as a potential diagnostic marker for asthma? J Asthma. 2014;51:847–854.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190.
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–171.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28–35.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhao F, Zhong J, et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One. 2015;10(9):e0136549.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001;108(4):503–508.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–1604.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–1141.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012 Feb;129(2):456–63, 463.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891–901.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20.
   PubMed Web of Science ®Google Scholar
• Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132(3):567–574.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–756.
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338.
   PubMed Web of Science ®Google Scholar
• Murray LA, Zhang H, Oak SR, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014;50(5):985–994.
   PubMed Web of Science ®Google Scholar
• Izuhara K, Conway SJ, Moore BB, et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016 Jan 12;193:949–956 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Hua F, Ribbing J, Reinisch W, et al. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharmacol. 2015 Jul;80(1):101–109.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Jun 3]. Available from: https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/
   Google Scholar
• Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10):910–917.
   PubMed Web of Science ®Google Scholar
• Ferrando M, Bagnasco D, Varricchi G, et al. Personalized medicine in allergy. Allergy Asthma Immunol Res. Forthcoming 2016.
   Google Scholar